The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
So, I really appreciate that you're saying that the classic psychedelics may offer with a very strong nudge, perhaps, the opportunity to get into the uncomfortable in a way that MDMA or some non-classical psychedelics, perhaps, do not.
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
But it's also-- it's a strength, because you well, the classics like psilocybin can take you there very reliably but maybe a bit aggressively. MDMA makes it easier to go there. And that's its strength.